Latest News & Features
Plant Varieties
Applicants face tough scrutiny for claims around the laws of nature, but details of new processes, steps or guidance can help patents pass the courts’ two-step test, says Michael Taylor of Harness IP. 26 March 2024
Big Pharma
US Patent Trial and Appeal Board sides with the biotech pair in their challenge against Moderna's mRNA vaccine patents | Inter partes review challenges broad claims and monopolisation over mRNA tech. 21 March 2024
Big Pharma
Pharma giant says defendant initially concealed new role at competitor | Employee allegedly took “vast amounts” of confidential information and accessed it while employed by Pfizer. 21 March 2024
Big Pharma
ViQual Medical Technology had accused Kaiser Foundation Health Plan of stealing secrets related to monitors for diabetes and other conditions | California judge says no evidence confidential information was taken or used. 19 March 2024
Big Pharma
Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details. 19 March 2024
Biotechnology
It is critical that the emerging field of personalised medicine receives appropriate patent protection, explain Joel Coles and Theo Cooper of Powell Gilbert. 14 March 2024
CRISPR
Japanese imaging and electronics firm has acquired non-exclusive licence from ERS Genomics | Technology will be used by Elixirgen Scientific, acquired by Ricoh in 2022. 14 March 2024
Big Pharma
Pharma company’s new partnership is an “opportunity” to accelerate access and maximise the potential of AstraZenica’s asthma drug | Delhi-based pharma firm will provide valuable distribution channels. 12 March 2024
Big Pharma
Danish drugmaker testing suspect products and assisting with legal cases | High demand and global shortages have driven surge in weight-loss drug fakes. 12 March 2024
Unified Patent Court
Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert. 7 March 2024